



08/25/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231
BOX: PATENT APPLICATIONS

August 25, 2000

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Paul B. Fisher, Dong-Chul Kang, and Zao-Zhong Su for
Inventor(s)

PROGRESSION SUPPRESSED GENE 13 (PSGen13) AND USES THEREOF
Title of Invention

Also enclosed are:

☒ 10 sheet(s) of ☐ informal ☒ formal drawings.

☒ Oath or declaration of Applicant(s). (unsigned)

☒ A power of attorney (unsigned)

☐ An assignment of the invention to _____

☒ A Preliminary Amendment

☐ A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	32 -20	=	12	X	\$ 9.00	\$18.00	= \$	\$ 216
Independent Claims	5 -3	=	2	X	\$39.00	\$78.00	= \$	\$ 156
Multiple Dependent Claims Presented: <u> X </u> Yes <u> </u> No					\$130.00	\$260.00	= \$	\$ 260
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE		\$	\$ 690
					TOTAL FEE		\$	\$1,322

jc-886 U.S. PTO
09/648310



08/25/00

☒ A check in the amount of \$ 1,322.00 to cover the filing fee.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

☒ Filing fees under 37 C.F.R. \$1.16.

☒ Patent application processing fees under 37 C.F.R. \$1.17.

☐ The issue fee set in 37 C.F.R. \$1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. \$1.311(b).

☒ Three copies of this sheet are enclosed.

☒ A certified copy of previously filed foreign application No. _____ filed in _____ on _____.

☒ Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.

☒ Other (identify) One extra loose set of formal drawings and an Express Mail Certificate of Mailing bearing label number EJ 900 852 215 US dated August 25, 2000.

Respectfully submitted,

John P. White

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Paul B. Fisher et al.
U.S. Serial No.: Not Yet Known
Filing date : Herewith
For : PROGRESSION SUPPRESSED GENE 13 (PSGen 13)
AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
August 25, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231
Box: Patent Application

SIR:

EXPRESS MAIL CERTIFICATE OF MAILING
FOR ABOVE-IDENTIFIED APPLICATION

"Express Mail" mailing label number: EJ 900 852 215 US
Date of Deposit: August 25, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

Printed Name: *John P. White* *Jane M. Love*

Respectfully submitted,

John P. White

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Paul B. Fisher et al.
U.S. Serial No.: Not Yet Known
Filing date : Herewith
For : PROGRESSION SUPPRESSED GENE 13 (PSGen 13)
AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
August 25, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Box: Patent Application

SIR:

PRELIMINARY AMENDMENT

Please amend the subject application as follows:

In the claims:

Please cancel claims 2-8, 11, 12, 23-25, 27-29, 31, 33, 35, 37-39, and 41-43 without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation, divisional or other application.

Thus, claims 1, 9, 10, 13-22, 26, 30, 32, 34, 36 and 40 are pending.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone at the number provided below.

Applicants: Paul B. Fisher, et al.
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 2

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorney for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

*Application
for
United States Letters Patent*

To all whom it may concern:

Be it known that **Paul B. Fisher, Dong-Chul Kang, and Zao-Zhong Su**
have invented certain new and useful improvements in
Progression Suppressed Gene 13 (PSGen 13) And Uses Thereof
of which the following is a full, clear and exact description.

Progression Suppressed Gene 13 (PSGen 13) And Uses Thereof

5 The invention disclosed herein was made with Government support under National Institutes of Health Grant No. CA35675 from the U.S. Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.

10 **Background of the Invention**

Throughout this application, various publications are referenced by author and date within the text. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding the claims. All patents, 15 patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order 20 to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

Summary of the Invention

The invention provides for an isolated nucleic acid encoding a Progression Suppressed Gene 13 (PSGen 13) protein. The
5 invention also provides a vector comprising said nucleic acid and a host cell comprising said vector. The invention provides for an isolated Progression Suppressed Gene 13 (PSGen 13) protein. The invention also provides a method for treating cancer in a subject which comprises contacting a cell of the
10 subject with a nucleic acid encoding a Progression Suppressed Gene 13 Protein (PSGen 13) in a sufficient amount so as to cause the cell to express the PSGen 13 protein, thereby treating cancer in the subject. The invention also provides a method for inhibiting growth of a cancer cell which comprises contacting the
15 cancer cell with a pharmaceutical composition comprising a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator compound in a sufficient amount so as to inhibit growth of the cancer cell.

Brief Description of the Figures

Figure 1. Nucleotide and predicted amino acid sequence of the rat PSGen 13 gene (designated PSGen 13). Starting ATG of the open reading frame and stop codon are bold faced and the poly(A) signal is underlined. (SEQ ID NOS: __ and __) ATCC Designation No. ____, which was deposited on August 24, 2000 under provisions of the Budapest Treaty with the American Type Culture Collection (see details hereinbelow).

Figure 2. Nucleotide and predicted amino acid sequence of the human PSGen 13, (designated HuPSGen 13) gene. Starting ATG of the open reading frame and stop codon are bold faced and the poly(A) signal is underlined. ATCC Designation No. ____, which was deposited on August 24, 2000 under provisions of the Budapest Treaty with the American Type Culture Collection (see details hereinbelow). (SEQ ID NOS: __ and __).

Figure 3. Nucleotide sequence comparison between the rat PSGen 13 and HuPSGen 13 cDNAs. The start and stop codons of the rat PSGen 13 and HuPSGen 13 genes are underlined. (SEQ ID NOS: __ and __).

Figure 4. Amino acid sequence comparison between the rat PSGen 13 and HuPSGen 13 encoded proteins. Conserved substitutions in the rat PSGen 13 and HuPSGen 13 proteins are underlined. (SEQ ID NOS: __ and __).

Figure 5. Differential expression of PSGen-13 identified by RSDD and reverse Northern blotting in a large panel of rodent cells displaying differences in transformation progression. A Northern blot of cells displaying various stages of transformation progression was probed with a radiolabeled (³²P) rat PSGen 13 cDNA initially identified by RSDD and reverse Northern blotting (6). The cell types used include unprogressed E11 (-), CREF X E11-NMT F1 (-) and CREF X E11-NMT F2 (-) somatic cell hybrids,

E11 X E11-NMT A6 (-) somatic cell hybrid, E11 X E11-NMT 3b (-) somatic cell hybrid, and E11-NMT AZA B1 (-) and E11-NMT AZA C1 (-) 5-azacytidine-treated E11-NMT clones; and progressed E11-NMT (+), CREF X E11-NMT R1 (+) and CREF X E11-NMT R2 (+) somatic cell hybrids, E11 X E11-NMT A6TD (+) nude mouse tumor derived somatic cell hybrid, E11 X E11-NMT IIa (+), E11-Ras R12 (+) and E11-HPV E6/E7 (+) and an E11 clone transformed by the E6 and E7 region of HPV-18. Equal loading of RNAs is demonstrated by ethidium bromide (EtBr) staining. Data from ref. 6.

Figure 6. PSGen 13 suppresses anchorage independent growth in E11-NMT cells. Agar cloning efficiency of the indicated cell types were determined as described previously (7-9). Cell types include, E11, E11-NMT and PSGen 13 transfected E11-NMT clones, designed as NMT-PSG13 c1 3, 5, 6, 7, 8, 9, 10, 11 and 12. Triplicate samples varied by < 10% and replicate assays varied by < 15%.

Figure 7. Northern blotting analysis of rat PSGen 13 and GAPDH expression in E11, E11-NMT and NMT-PSG13 clones. Fifteen micrograms of cellular RNA isolated from the indicated cell types were electrophoresed, transferred to nylon membranes and hybridized with a rat PSGen 13 cDNA and then stripped and probed with GAPDH as previously described (11,12).

Figure 8. Rat PSGen 13 inhibits anchorage independent growth in DU-145 human prostate carcinoma cells. Agar cloning efficiency of the indicated cell types were determined as described previously (7-0). Cell types include, CD-145, DU-145 vector transformed clone (DU-145/Vec) and rat PSGen 13 transfected DU-145 clones, designed as DU-PSG13 c1 11, 12, 13, 14, 15 and 17. Triplicate samples varied by <10% and replicate assays varied by <12%.

Figure 9. Full length PEG-3 promoter-luciferase activity in E11,

E11-NMT and NMT-PSG13 clones. Different cell types were co-transfected with 5 μ g of the full length PEG-Prom and 1 μ g of a pSV- β -galactosidase plasmid and luciferase activity was determined as described in Materials and Methods 48 hr later. The results are standardized by β -galactosidase activity and represent the average of 3 independent experiments that varied by < 15%.

Figure 10. VEGF promoter-luciferase activity in E11, E11-NMT and NMT-PSG13 clones. Different cell types were co-transfected with 5 μ g of the VEGF-Prom-luciferase (12) and 1 μ g of a pSV- β -galactosidase plasmid and luciferase activity was determined as described in Materials and Methods 48 hr later. The results are standardized by β -galactosidase activity and represent the average of 3 independent experiments that varied by < 15%.

Detailed Description of the Invention

Throughout this application, references to specific nucleotides are to nucleotides present on the coding strand of the nucleic acid. The following standard abbreviations are used throughout

5 the specification to indicate specific nucleotides:

C=cytosine	A=adenosine
T=thymidine	G=guanosine

10 The invention provides for an isolated nucleic acid encoding a Progression Suppressed Gene 13 (PSGen 13) protein. In one embodiment of the invention, the Progression Suppressed Gene 13 (PSGen 13) protein is a human protein, a rat protein, a primate protein, a mouse protein, or a bovine protein. In another embodiment of the invention, the nucleic acid comprises the polynucleotide sequence shown in SEQ ID NO:1. In another embodiment of the invention, the nucleic acid comprises the polynucleotide sequence shown in SEQ ID NO:2. In another embodiment of the invention, the nucleic acid consists essentially of the polynucleotide sequence shown in SEQ ID NO:1. In another embodiment of the invention, the nucleic acid consists essentially of the polynucleotide sequence shown in SEQ ID NO:2.

15 In another embodiment of the invention, the nucleic acid consists of the polynucleotide sequence shown in SEQ ID NO:1. In another embodiment of the invention, the nucleic acid consists of the polynucleotide sequence shown in SEQ ID NO:2.

20 The invention provides for a vector comprising the nucleic acid described herein. The invention also provides for a host cell comprising the vector. In one embodiment, the host cell is a tumor cell. In another embodiment, the tumor cell is a nasopharyngeal tumor cell, a thyroid tumor cell, a central nervous system tumor cell, a melanoma cell, an epithelial tumor cell, a non-epithelial tumor cell, a blood tumor cell, a leukemia

25

30

35

cell, a lymphoma cell, a neuroblastoma cell, a cervical cancer cell, a breast cancer cell, a lung cancer cell, a prostate cancer cell, a colon cancer cell or a glioblastoma multiforme cell.

5 The invention provides for a method for treating cancer in a subject which comprises contacting a cell of the subject with a nucleic acid encoding a Progression Suppressed Gene 13 Protein (PSGen 13) in a sufficient amount so as to cause the cell to express the PSGen 13 protein, thereby treating cancer in the
10 subject. In one embodiment of the invention, the cell is a tumor cell. In another embodiment of the invention, the tumor cell is a nasopharyngeal tumor cell, a thyroid tumor cell, a central nervous system tumor cell, a melanoma cell, an epithelial tumor cell, a non-epithelial tumor cell, a blood tumor cell, a leukemia cell, a lymphoma cell, melanoma cell, a neuroblastoma cell, a
15 cervical cancer cell, a breast cancer cell, a lung cancer cell, a prostate cancer cell, a colon cancer cell or a glioblastoma multiforme cell.

20 In another embodiment of the invention, the subject is suffering from a form of cancer. In another embodiment of the invention, the form of cancer is melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, chondrosarcoma, a
25 nasopharyngeal tumor, a thyroid tumor, a central nervous system tumor, a melanoma, an epithelial tumor, a non-epithelial tumor, a blood tumor, a leukemia, a lymphoma.

30 In another embodiment of the invention, the contacting is by way of topical application, administration to the subject, injection, electroporation, liposome application, viral-mediated contact, contacting the cell with the nucleic acid, or coculturing the cell with the nucleic acid.

35 In another embodiment of the invention, the contacting is carried out via injection, oral administration, topical administration,

adenovirus infection, viral-mediated infection, liposome-mediated transfer, topical application to the cells of the subject, or microinjection.

- 5 In another embodiment of the invention, the subject is a mammal.
In another embodiment of the invention, the mammal is a human.

10 The invention provides for an isolated Progression Suppressed Gene 13 (PSGen 13) protein. In one embodiment of the invention, the protein is a human protein, a rat protein, a bovine protein, a mouse protein, or a primate protein. In another embodiment of the invention, the protein has a polypeptide sequence which is encoded by the polynucleotide sequence of SEQ ID NO:1. In another embodiment of the invention, the protein has a polypeptide sequence which is encoded by the polynucleotide sequence of SEQ ID NO:2.

15 The invention provides for an antibody which binds specifically to the protein described herein. In another embodiment of the invention, the antibody is a polyclonal antibody or a monoclonal antibody. In another embodiment of the invention, the antibody is a human antibody, a murine antibody, a primate antibody, a bovine antibody, a sheep antibody or a rat antibody. In another embodiment of the invention, the antibody is a human monoclonal antibody, a humanized murine monoclonal antibody, a humanized primate monoclonal antibody, or a humanized rat monoclonal antibody.

20 The invention provides for a composition which comprises any one of the nucleic acids described herein. In another embodiment of the invention, the composition is a pharmaceutical composition.

25 The invention provides for a composition which comprises any one of the proteins described herein and a carrier. In another embodiment of the invention, the composition is a pharmaceutical composition.

The invention provides for a composition which comprises the antibody described herein and a carrier. In another embodiment of the invention, the composition is a pharmaceutical composition.

5 The invention provides for a method for inhibiting growth of a cancer cell which comprises contacting the cancer cell with a pharmaceutical composition comprising a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator
10 compound in a sufficient amount so as to inhibit growth of the cancer cell. In another embodiment of the invention, the PSGen 13 activator compound comprises a transcription factor which specifically activates expression of a PSGen 13 gene, an agent which prolongs PSGen 13 protein half-life in the cell, or a compound which stabilizes PSGen 13 mRNA in the cell so as to
15 increase translation of PSGen 13 protein in the cell. In another embodiment of the invention, the contacting is by way of topical application, injection, electroporation, liposome application, or coculturing the cell with the nucleic acid. In another
20 embodiment of the invention, the cancer cell is a nasopharyngeal tumor cell, a thyroid tumor cell, a central nervous system tumor cell, a melanoma cell, an epithelial tumor cell, a non-epithelial tumor cell, a blood tumor cell, a leukemia cell, a lymphoma cell, a melanoma cell, a neuroblastoma cell, a cervical cancer cell,
25 a breast cancer cell, a lung cancer cell, a prostate cancer cell, a colon cancer cell or a glioblastoma multiforme cell.

The invention provides for a method for inhibiting angiogenesis associated with tumor growth in a subject which comprises
30 administering to the subject a pharmaceutical composition comprising a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator compound in a sufficient amount so as to inhibit angiogenesis associated with tumor growth in the subject. In another embodiment of the invention, the
35 subject is a mammal. In another embodiment of the invention, the mammal is a human. In another embodiment of the invention, the

subject is suffering from melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, chondrosarcoma, a nasopharyngeal tumor, a thyroid tumor, a central nervous system tumor, a melanoma, an epithelial tumor, a non-epithelial tumor, a blood tumor, a leukemia, or a lymphoma.

Biological Deposit

10 The invention provides for a nucleic acid encoding PSGen 13 (rat protein, which nucleic acid, designated PSGen 13, ATCC Designation No. _____, deposited August 24, 2000 with the American Type Culture Collection (ATCC), 10801 University Blvd, Manassas, Virginia, 20110-2209 under the provision of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. This deposit is an insert within a plasmid vector, pcDNA3.1(+). It is within the EcoRI-Xho I cloning site. The insert is about 0.8 kb in length. The sense strand promoter of the plasmid is T7. 15 The plasmid carries resistance genes to ampicillin and neomycin. The insert origin is EST clone ATCC #2005777. The rat tissue used to isolate the DNA was adrenal gland tissue. 20

The invention provides for a nucleic acid encoding HuPSGen 13 (human) protein, which nucleic acid, designated HuPSGen 13, ATCC Designation No. _____, deposited August 24, 2000 with the American Type Culture Collection (ATCC), 10801 University Blvd, Manassas, Virginia, 20110-2209 under the provision of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. This deposit is an insert within a plasmid vector, pT7T3-Pac. It is within the EcoRI-Not I cloning site. The insert is about 0.83 kb in length. The plasmid carries a resistance gene to ampicillin. The insert origin is EST clone #2525262. The human tissue used to isolate the DNA was human kidney tissue. 25 30 35

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA technology, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g.,
5 Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989); DNA Cloning, Vols. I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins
10 eds. 1984); Animal Cell Culture (R. K. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL press, 1986); Perbal, B., A Practical Guide to Molecular Cloning (1984); the series, Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); and Handbook of Experimental Immunology, Vols. I-IV (D.
15 M. Weir and C. C. Blackwell eds., 1986, Blackwell Scientific Publications).

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references
20 unless the content clearly dictates otherwise.

In an embodiment of the invention, the host cell is stably transformed with the recombinant expression construct described herein. In another embodiment of the invention, the host cell
25 is a tumor cell. In another embodiment of the invention, the cell is an immortalized cell.

In another embodiment of the invention, the tumor cell is a melanoma cell, a neuroblastoma cell, an astrocytoma cell, a
30 glioblastoma cell, a gliosarcoma cell, a cervical cancer cell, a breast cancer cell, a lung cancer cell or a prostate cancer cell.

In another embodiment of the invention, the "introducing" or "contacting" is carried out by a means selected from the group
35 consisting of adenovirus infection, liposome-mediated transfer,

topical application to the cell, and microinjection.

In another embodiment of the invention, the cancer is melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, or chondrosarcoma.

In another embodiment of the invention, the cancer is a cancer of the central nervous system of the subject.

In another embodiment of the invention, the administering is carried out via injection, oral administration, or topical administration.

In another embodiment of the invention, the carrier is an aqueous carrier, a liposome, or a lipid carrier.

Definitions

As used herein "therapeutic gene" means DNA encoding an amino acid sequence corresponding to a functional protein capable of exerting a therapeutic effect on cancer cells or having a regulatory effect on the expression of a function in cells, especially in skin cells (melanocytes).

As used herein "nucleic acid molecule" includes both DNA and RNA and, unless otherwise specified, includes both double-stranded and single-stranded nucleic acids. Also included are hybrids such as DNA-RNA hybrids. Reference to a nucleic acid sequence can also include modified bases as long as the modification does not significantly interfere either with binding of a ligand such as a protein by the nucleic acid or Watson-Crick base pairing.

As used herein "enhancer element" is a nucleotide sequence that increases the rate of transcription of the therapeutic genes or

genes of interest but does not have promoter activity. An enhancer can be moved upstream, downstream, and to the other side of a promoter without significant loss of activity.

Two DNA or polypeptide sequences are "substantially homologous" when at least about 80% (preferably at least about 90%, and most preferably at least about 95%) of the nucleotides or amino acids match over a defined length of the molecule. As used herein, "substantially homologous" also refers to sequences showing identity to the specified DNA or polypeptide sequence. DNA sequences that are substantially homologous can be identified in a Southern hybridization, experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; DNA Cloning, vols I & II, supra; Nucleic Acid Hybridization, supra.

A DNA "coding sequence" or a "nucleotide sequence encoding" a particular protein, is a DNA sequence which is transcribed and translated into a polypeptide *in vivo* or *in vitro* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5'-(amino) terminus and a translation stop codon at the 3'-(carboxy) terminus. A coding sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) sources, viral RNA or DNA, and even synthetic nucleotide sequences. A transcription termination sequence will usually be located 3' to the coding sequence.

DNA "control sequences" refers collectively to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, untranslated regions, including 5'-UTRs and 3'-UTRs, which collectively provide for the transcription and translation of a coding sequence in a host cell.

"Operably linked" refers to an arrangement of nucleotide sequence elements wherein the components so described are configured so as to perform their usual function. Thus, control sequences operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control sequences need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

A control sequence "directs the transcription" of a coding sequence in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.

A cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In procaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. In eucaryotic cells, a stably transformed cell is generally one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication, or one which includes stably maintained extrachromosomal plasmids. This stability is demonstrated by the ability of the eucaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the exogenous DNA.

A "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature. An example of a heterologous coding sequence is a construct where

the coding sequence itself (e.g., the coding sequence of PSGen 13 mutant or fragment of nucleic acid encoding PSGen 13) is not found in nature (e.g., synthetic sequences having codons different from the native gene). Likewise, a chimeric sequence, comprising a heterologous structural gene and a gene encoding a PSGen 13 or a portion of such gene, linked to a tissue specific promoter, whether derived from the same or a different gene, will be considered heterologous since such chimeric constructs are not normally found in nature. Allelic variation or naturally occurring mutational events do not give rise to a heterologous region of DNA, as used herein.

Vectors

Especially preferred are virus based vectors. In the case of eukaryotic cells, retrovirus or adenovirus based vectors are preferred. Such vectors contain all or a part of a viral genome, such as long term repeats ("LTRs"), promoters (e.g., CMV promoters, SV40 promoter, RSV promoter), enhancers, and so forth. When the host cell is a prokaryote, bacterial viruses, or phages, are preferred. Exemplary of such vectors are vectors based upon, e.g., lambda phage. In any case, the vector may comprise elements of more than one virus.

The resulting vectors are transfected or transformed into a host cell, which may be eukaryotic or prokaryotic. The gene transfer vector of the present invention may additionally comprise a gene encoding a marker or reporter molecule to more easily trace expression of the vector. The particular reporter molecule which can be employed in the present invention is not critical thereto. Examples of such reporter molecules which can be employed in the present invention are well-known in the art and include beta-galactosidase (Fowler et al, Proc. Natl. Acad. Sci., USA, 74:1507 (1977)), luciferase (Tu et al, Biochem., 14:1970 (1975)), and chloramphenicol acetyltransferase (Gorman et al, Mol. Cell Biol., 2:1044-1051 (1982)). The gene transfer vector may contain more

than one gene encoding the same or different foreign polypeptides or RNAs. The gene transfer vector may be any construct which is able to replicate within a host cell and includes plasmids, DNA viruses, retroviruses, as well as isolated nucleotide molecules. Liposome-mediated transfer of the gene transfer vector may also be carried out in the present invention. Examples of such plasmids which can be employed in the present invention include pGL3-based plasmids (Promega). An example of such DNA viruses which can be employed in the present invention are adenoviruses.

Adenoviruses have attracted increasing attention as expression vectors, especially for human gene therapy (Berkner, Curr. Top. Microbiol. Immunol., 158:39-66 (1992)). Examples of such adenovirus serotypes which can be employed in the present invention are well-known in the art and include more than 40 different human adenoviruses, e.g., Ad12 (subgenus A), Ad3 and Ad7 (Subgenus B), Ad2 and Ad5 (Subgenus C), Ad8 (Subgenus D), Ad4 (Subgenus E), Ad40 (Subgenus F) (Wigand et al, In: Adenovirus DNA, Doerfler, Ed., Martinus Nijhoff Publishing, Boston, pp. 408-441 (1986)). Ad5 of subgroup C is the preferred adenovirus employed in the present invention. This is because Ad5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector. Also, adenoviral vectors are commercially available, e.g., pCA3 (Microbix Biosystems Inc.).

Methods for producing adenovirus vectors are well-known in the art (Berkner et al, Nucleic Acids Res., 11:6003-6020 (1983); van Doren et al, Mol. Cell. Biol., 4:1653-1656 (1984); Ghosh-Choudhury et al, Biochem. Biophys. Res. Commun., 147:964-973 (1987); McGrory et al, Virol., 163:614-617 (1988); and Gluzman et al, In: Eukaryotic Viral Vectors, Ed. Gluzman, Y. pages 187-192, Cold Spring Harbor Laboratory (1982)).

Derivative nucleic acid molecules

Derivative molecules would retain the functional property of the PSGen 13, namely, the molecule having such substitutions will still have the same or similar biological activity of PSGen 13 (that is to suppress the cancer phenotype or inhibit growth of cancer cells). Modification is permitted so long as the derivative molecules retain its increased potency compared to a normally occurring PSGen 13 protein. The purpose of the therapeutic gene is to inhibit the growth of cancer cells or produce cytokines or other cytotoxic agents which directly or indirectly inhibit the growth of or kill the cancer cell.

Preferred vectors for use in the methods of the present invention are viral including adenoviruses, retroviral, vectors, adeno-associated viral (AAV) vectors. The viral vector selected should meet the following criteria: 1) the vector must be able to infect the tumor cells and thus viral vectors having an appropriate host range must be selected; 2) the transferred gene should be capable of persisting and being expressed in a cell for an extended period of time; and 3) the vector should be safe to the host and cause minimal cell transformation. Retroviral vectors and adenoviruses offer an efficient, useful, and presently the best-characterized means of introducing and expressing foreign genes efficiently in mammalian cells. These vectors have very broad host and cell type ranges, express genes stably and efficiently. The safety of these vectors has been proved by many research groups. In fact many are in clinical trials.

Other virus vectors that may be used for gene transfer into cells for correction of disorders include retroviruses such as Moloney murine leukemia virus (MoMuLV); papovaviruses such as JC, SV40, polyoma, adenoviruses; Epstein-Barr Virus (EBV); papilloma viruses, e.g. bovine papilloma virus type I (BPV); vaccinia and

poliovirus and other human and animal viruses.

Adenoviruses have several properties that make them attractive as cloning vehicles (Bachettis et al.: Transfer of gene for thymidine kinase-deficient human cells by purified herpes simplex viral DNA. PNAS USA, 1977 74:1590; Berkner, K. L.: Development of adenovirus vectors for expression of heterologous genes. Biotechniques, 1988 6:616; Ghosh-Choudhury G., et al., Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 1986; 50:161; Hag-Ahmand Y., et al., Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J Virol 1986; 57:257; Rosenfeld M., et al., Adenovirus-mediated transfer of a recombinant .alpha..sub.1 -antitrypsin gene to the lung epithelium in vivo. Science 1991; 252:431).

For example, adenoviruses possess an intermediate sized genome that replicates in cellular nuclei; many serotypes are clinically innocuous; adenovirus genomes appear to be stable despite insertion of foreign genes; foreign genes appear to be maintained without loss or rearrangement; and adenoviruses can be used as high level transient expression vectors with an expression period up to 4 weeks to several months. Extensive biochemical and genetic studies suggest that it is possible to substitute up to 7-7.5 kb of heterologous sequences for native adenovirus sequences generating viable, conditional, helper-independent vectors (Kaufman R. J.; identification of the component necessary for adenovirus translational control and their utilization in cDNA expression vectors. PNAS USA, 1985 82:689).

AAV is a small human parvovirus with a single stranded DNA genome of approximately 5 kb. This virus can be propagated as an integrated provirus in several human cell types. AAV vectors have several advantage for human gene therapy. For example, they are trophic for human cells but can also infect other mammalian cells; (2) no disease has been associated with AAV in humans or

other animals; (3) integrated AAV genomes appear stable in their host cells; (4) there is no evidence that integration of AAV alters expression of host genes or promoters or promotes their rearrangement; (5) introduced genes can be rescued from the host cell by infection with a helper virus such as adenovirus.

HSV-1 vector system facilitates introduction of virtually any gene into non-mitotic cells (Geller et al. an efficient deletion mutant packaging system for a defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology. PNAS USA, 1990 87:8950).

Another vector for mammalian gene transfer is the bovine papilloma virus-based vector (Sarver N, et al., Bovine papilloma virus DNA: A novel eukaryotic cloning vector. Mol Cell Biol 1981; 1:486). Vaccinia and other poxvirus-based vectors provide a mammalian gene transfer system. Vaccinia virus is a large double-stranded DNA virus of 120 kilodaltons (kd) genomic size (Panicali D, et al., Construction of poxvirus as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982; 79:4927; Smith et al. infectious vaccinia virus recombinants that express hepatitis B virus surface antigens. Nature, 1983 302:490.)

Retroviruses are packages designed to insert viral genes into host cells (Guild B, et al., Development of retrovirus vectors useful for expressing genes in cultured murine embryonic cells and hematopoietic cells in vivo. J Virol 1988; 62:795; Hock R. A., et al., Retrovirus mediated transfer and expression of drug resistance genes in human hemopoietic progenitor cells. Nature 1986; 320:275). The basic retrovirus consists of two identical strands of RNA packaged in a proviral protein. The core surrounded by a protective coat called the envelope, which is derived from the membrane of the previous host but modified with glycoproteins contributed by the virus.

Markers and amplifiers can also be employed in the subject expression systems. A variety of markers are known which are useful in selecting for transformed cell lines and generally comprise a gene whose expression confers a selectable phenotype on transformed cells when the cells are grown in an appropriate selective medium. Such markers for mammalian cell lines include, for example, the bacterial xanthine-guanine phosphoribosyl transferase gene, which can be selected for in medium containing mycophenolic acid and xanthine (Mulligan et al. (1981) Proc. Natl. Acad. Sci. USA 78:2072-2076), and the aminoglycoside phosphotransferase gene (specifying a protein that inactivates the antibacterial action of neomycin/kanamycin derivatives), which can be selected for using medium containing neomycin derivatives such as G418 which are normally toxic to mammalian cells (Colbere-Garapin et al. (1981) J. Mol. Biol. 150:1-14). Useful markers for other eucaryotic expression systems, are well known to those of skill in the art.

Infection can be carried out *in vitro* or *in vivo*. *In vitro* infection of cells is performed by adding the gene transfer vectors to the cell culture medium. When infection is carried out *in vivo*, the solution containing the gene transfer vectors may be administered by a variety of modes, depending on the tissue which is to be infected. Examples of such modes of administration include injection of gene transfer vectors into the skin, topical application onto the skin, direct application to a surface of epithelium, or instillation into an organ (e.g., time release patch or capsule below the skin or into a tumor).

Expression can be amplified by placing an amplifiable gene, such as the mouse dihydrofolate reductase (dhfr) gene adjacent to the coding sequence. Cells can then be selected for methotrexate resistance in dhfr-deficient cells. See, e.g. Urlaub et al. (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220; Rungold et al. (1981) J. Mol. and Appl. Genet. 1:165-175.

The above-described system can be used to direct the expression of a wide variety of procaryotic, eucaryotic and viral proteins, including, for example, viral glycoproteins suitable for use as vaccine antigens, immunomodulators for regulation of the immune response, hormones, cytokines and growth factors, as well as proteins useful in the production of other biopharmaceuticals.

It may also be desirable to produce mutants or analogs of the PSCGen 13 proteins or nucleic acids. Mutants or analogs may be prepared by the deletion of a portion of the sequence encoding the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et al., supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra. The mutants would be useful if they, for example, had a prolonged half-life in the tumor cell, thereby having a greater effect on the tumor cell; were more bioavailable; were more easily located to the target cell of interest due to a fused protein or targeting portion; were more efficacious; were more potent; etc. The methods for making mutations and analogs of a known sequenced nucleic acid or protein are well known to one of skill in the art.

In one embodiment of the invention, a heterologous gene sequence, i.e., a therapeutic gene, is inserted into the nucleic acid molecule of the invention. Other embodiments of the isolated nucleic acid molecule of the invention include the addition of a single enhancer element or multiple enhancer elements which amplify the expression of the heterologous therapeutic gene without compromising tissue specificity.

The transformation procedure used depends upon the host to be

transformed. Mammalian cells can conveniently be transformed using, for example, DEAE-dextran based procedures, calcium phosphate precipitation (Graham, F. L. and Van der Eb, A. J. (1973) *Virology* 52:456-467), protoplast fusion, liposome-mediated transfer, polybrene-mediated transfection and direct microinjection of the DNA into nuclei. Bacterial cells will generally be transformed using calcium chloride, either alone or in combination with other divalent cations and DMSO (Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989)). DNA can also be introduced into bacterial cells by electroporation. Methods of introducing exogenous DNA into yeast hosts typically include either the transformation of spheroplasts or transformation of intact yeast cells treated with alkali cations.

The constructs can also be used in gene therapy or nucleic acid immunization, to direct the production of the desired gene product in vivo, by administering the expression constructs directly to a subject for the in vivo translation thereof. See, e.g. EPA Publication No. 336,523 (Dreano et al., published Oct. 11, 1989). Alternatively, gene transfer can be accomplished by transfecting the subject's cells or tissues with the expression constructs ex vivo and reintroducing the transformed material into the host. The constructs can be directly introduced into the host organism, i.e., by injection (see International Publication No. WO/90/11092; and Wolff et al., (1990) *Science* 247:1465-1468). Liposome-mediated gene transfer can also be accomplished using known methods. See, e.g., Hazinski et al., (1991) *Am. J. Respir. Cell Mol. Biol.* 4:206-209; Brigham et al. (1989) *Am. J. Med. Sci.* 298:278-281; Canonico et al. (1991) *Clin. Res.* 39:219A; and Nabel et al. (1990) *Science* 249:1285-1288. Targeting agents, such as antibodies directed against surface antigens expressed on specific cell types, can be covalently conjugated to the liposomal surface so that the nucleic acid can be delivered to specific tissues and cells for local administration.

Human Gene Therapy and Diagnostic Use of Vector

There are several protocols for human gene therapy which have been approved for use by the Recombinant DNA Advisory Committee (RAC) which conform to a general protocol of target cell infection and administration of transfected cells (see for example, Blaese, R.M., et al., 1990; Anderson, W. F., 1992; Culver, K.W. et al., 1991). In addition, U.S. Patent No. 5,399,346 (Anderson, W. F. et al., March 21, 1995, U.S. Serial No. 220,175) describes procedures for retroviral gene transfer. The contents of these support references are incorporated in their entirety into the subject application. Retroviral-mediated gene transfer requires target cells which are undergoing cell division in order to achieve stable integration hence, cells are collected from a subject often by removing blood or bone marrow. It may be necessary to select for a particular subpopulation of the originally harvested cells for use in the infection protocol. Then, a retroviral vector containing the gene(s) of interest would be mixed into the culture medium. The vector binds to the surface of the subject's cells, enters the cells and inserts the gene of interest randomly into a chromosome. The gene of interest is now stably integrated and will remain in place and be passed to all of the daughter cells as the cells grow in number. The cells may be expanded in culture for a total of 9-10 days before reinfusion (Culver et al., 1991). As the length of time the target cells are left in culture increases, the possibility of contamination also increases, therefore a shorter protocol would be more beneficial.

Uses of the Compositions of the Invention

This invention involves targeting a composition which comprises a nucleic acid encoding a PSGen 13 protein; a PSGen 13 protein itself, a fragment, analog or mutant thereof; or a PSGen 13 activator compound (all of which are pharmaceutically acceptable)

to a cancer cell so that the cancer cell's growth is inhibited or reduced or stopped and the cancerous phenotype or condition is ameliorated. The composition which comprises a nucleic acid comprising a sequence encoding PSCGen 13 may also include a nucleic acid sequence which is a tissue specific promoter. This promoter, in one embodiment, is specifically active in the cell type which is cell type wherein the subject has cancer. For example, if the subject is suffering from breast cancer, the PSCGen 13 nucleic acid sequence could be operably linked to a promoter which will specifically be active (i.e., drive expression of a downstream coding sequence) in breast tissue.

After infecting a susceptible cell, the transgene driven by a specific promoter in the vector expresses the protein encoded by the gene. The use of the highly specific gene vector will allow selective expression of the specific genes in cancer cells.

The present invention provides packaging the cloned genes, i.e. the genes of interest, in such a way that they can be injected directly into the bloodstream or relevant organs of patients who need them. The packaging will protect the foreign DNA from elimination by the immune system and direct it to appropriate tissues or cells.

The methods described below are merely for purposes of illustration and are typical of those that might be used. However, other procedures may also be employed, as is understood in the art. Most of the techniques used to construct vectors and the like are widely practiced in the art, and most practitioners are familiar with the standard resource materials which describe specific conditions and procedures. However, for convenience, the following paragraphs may serve as a guideline.

General Methods for Vector Construction

Construction of suitable vectors containing the desired

therapeutic gene coding and control sequences employs standard ligation and restriction techniques, which are well understood in the art (see Maniatis et al., in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1982)). Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired.

Site-specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes (See, e.g. New England Biolabs Product Catalog). In general, about 1 μ g of plasmid or DNA sequences is cleaved by one unit of enzyme in about 20 μ l of buffer solution. Typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate.

Incubation times of about one hour to two hours at about 37 degree. C. are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology 65:499-560 (1980). Restriction cleaved fragments may be blunt ended by treating with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20.degree. C. to 25.degree. C. in 50 mM Tris (pH 7.6) 50 mM NaCl, 6 mM MgCl.sub.2, 6 mM DTT and 5-10 .mu.M dNTPs. The Klenow fragment fills in at 5' sticky ends but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by

supplying only one of the dNTPs, or with selected dNTPs, within the limitations dictated by the nature of the sticky ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or Bal-31 results in hydrolysis of any single-stranded portion.

Ligations are performed in 10-50 μ l volumes under the following standard conditions and temperatures using T4 DNA ligase. Ligation protocols are standard (D. Goeddel (ed.) Gene Expression Technology: Methods in Enzymology (1991)). In vector construction employing "vector fragments", the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase (CIP) in order to remove the 5' phosphate and prevent religation of the vector. Alternatively, religation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments.

Suitable vectors include viral vector systems e.g. ADV, RV, and AAV (R. J. Kaufman "Vectors used for expression in mammalian cells" in Gene Expression Technology, edited by D. V. Goeddel (1991)).

Many methods for inserting functional DNA transgenes into cells are known in the art. For example, non-vector methods include nonviral physical transfection of DNA into cells; for example, microinjection (DePamphilis et al., BioTechnique 6:662-680 (1988)); liposomal mediated transfection (Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987), Felgner and Holm, Focus 11:21-25 (1989) and Felgner et al., Proc. West. Pharmacol. Soc. 32: 115-121 (1989)) and other methods known in the art.

Administration of Modified Vectors Into Subject

One way to get DNA into a target cell is to put it inside a

membrane bound sac or vesicle such as a spheroplast or liposome, or by calcium phosphate precipitation (CaPO.sub.4) (Graham F. and Van der Eb, A., Virology 52:456 1973; Schaefer-Ridder M., et al., Liposomes as gene carriers: Efficient transduction of mouse L cells by thymidine kinase gene. Science 1982; 215:166; Stavridis J. C., et al., Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. Exp Cell Res 1986; 164:568-572).

A vesicle can be constructed in such a way that its membrane will fuse with the outer membrane of a target cell. The vector of the invention in vesicles can home into the cancer cells.

The spheroplasts are maintained in high ionic strength buffer until they can be fused through the mammalian target cell using fusogens such as polyethylene glycol.

Liposomes are artificial phospholipid vesicles. Vesicles range in size from 0.2 to 4.0 micrometers and can entrap 10% to 40% of an aqueous buffer containing macromolecules. The liposomes protect the DNA from nucleases and facilitate its introduction into target cells. Transfection can also occur through electroporation. Before administration, the modified vectors are suspended in complete PBS at a selected density for injection. In addition to PBS, any osmotically balanced solution which is physiologically compatible with the subject may be used to suspend and inject the modified vectors into the host.

For injection, the cell suspension is drawn up into the syringe and administered to anesthetized recipients. Multiple injections may be made using this procedure. The viral suspension procedure thus permits administration of genetically modified vectors to any predetermined site in the skin, is relatively non-traumatic, allows multiple administrations simultaneously in several different sites or the same site using the same viral suspension. Multiple injections may consist of a mixture of therapeutic

genes.

Survival of the Modified Vectors So Administered

5 Expression of a gene is controlled at the transcription, translation or post-translation levels. Transcription initiation is an early and critical event in gene expression. This depends on the promoter and enhancer sequences and is influenced by specific cellular factors that interact with these sequences. The transcriptional unit of many prokaryotic genes consists of the promoter and in some cases enhancer or regulator elements (Banerji et al., Cell 27:299 (1981); Corden et al., Science 209:1406 (1980); and Breathnach and Chambon, Ann. Rev. Biochem. 50:349 (1981)). For retroviruses, control elements involved in the replication of the retroviral genome reside in the long terminal repeat (LTR) (Weiss et al., eds., In: The molecular biology of tumor viruses: RNA tumor viruses, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982)).

20 Moloney murine leukemia virus (MLV) and Rous sarcoma virus (RSV) LTRs contain promoter and enhancer sequences (Jolly et al., Nucleic Acids Res. 11:1855 (1983); Capecchi et al., In: Enhancer and eukaryotic gene expression, Gulzman and Shenk, eds., pp. 101-102, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y.).

25 Promoter and enhancer regions of a number of non-viral promoters have also been described (Schmidt et al., Nature 314:285 (1985); Rossi and de Crombrughe, Proc. Natl. Acad. Sci. USA 84:5590-5594 (1987)).

30 The present invention provides methods for maintaining and increasing expression of therapeutic genes using a skin specific promoter.

35 In addition to using viral and non-viral promoters to drive

therapeutic gene expression, an enhancer sequence may be used to increase the level of therapeutic gene expression. Enhancers can increase the transcriptional activity not only of their native gene but also of some foreign genes (Armstrong, Proc. Natl. Acad. Sci. USA 70:2702 (1973)).

Therapeutic gene expression may also be increased for long term stable expression after injection using cytokines to modulate promoter activity.

The methods of the invention are exemplified by preferred embodiments in which modified vectors carrying a therapeutic gene are injected intracerebrally into a subject.

The most effective mode of administration and dosage regimen for the molecules of the present invention depends upon the exact location of the cancer being treated, the severity and course of the cancer, the subject's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the molecules should be titrated to the individual subject. The molecules may be delivered directly or indirectly via another cell, autologous cells are preferred, but heterologous cells are encompassed within the scope of the invention.

The interrelationship of dosages for animals of various sizes and species and humans based on mg/m² of surface area is described by Freireich, E. J., et al. Cancer Chemother., Rep. 50 (4):219-244 (1966). Adjustments in the dosage regimen may be made to optimize the tumor cell growth inhibiting and killing response, e.g., doses may be divided and administered on a daily basis or the dose reduced proportionally depending upon the situation (e.g., several divided dose may be administered daily or proportionally reduced depending on the specific therapeutic situation).

It would be clear that the dose of the molecules of the invention

required to achieve cures may be further reduced with schedule optimization.

5 This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221

EXPERIMENTAL DETAILS

Example 1: Progression Suppressed Gene 13 (PSGen 13) Inhibits the Transformed State in Rodent and Human Cancer Cells

A reciprocal subtraction differentiation RNA display (RSDD) approach has been developed that permits the efficient identification and cloning of differentially expressed genes. RSDD has been applied to cancer progression to identify genes with enhanced expression in unprogressed and progressed tumor cells. Using adenovirus transformed rodent cells displaying stable changes in expression of the transformed phenotype; RSDD permitted the cloning of an expressed sequence tag (EST) designated PSGen 13 that displays elevated expression in unprogressed versus progressed transformed cells. A full-length rodent PSGen 13 gene was generated, placed in an expression vector and stably transfected into a progressed rodent transformed cell line, E11-NMT, and the DU-145 human prostate carcinoma cell line. A series of random single cell clones were isolated and evaluated for expression of the transformed state as documented by their ability to grow in an anchorage independent manner. Specific E11-NMT and DU-145 clones transfected with the rat PSGen 13 expression vector, but not the control expression vector lacking the rat PSGen 13 gene, were inhibited in their ability to grow in an anchorage independent manner. In the case of E11-NMT transformants transfected with rat PSGen 13, transcription of a specific progression elevated gene, PEG-3, and the vascular endothelial growth factor (VEGF) gene was inhibited. Using the rat PSGen 13 sequence, a human PSGen 13, HuPSGen 13, gene with significant DNA and protein sequence homology, 75 and 94%, respectively, to the rat PSGen 13 gene has been identified. The present studies demonstrate that PSGen 13 is a suppressor of the cancer phenotype and suppression may involve changes in the expression of cancer progression inducing and angiogenesis stimulating genes. In these contexts, PSGen 13 may prove amenable for the gene-based therapy of human cancer.

OVERVIEW

Cancer is a progressive disease involving changes in the expression of genes that either stimulate or inhibit the carcinogenic process (1-5). Using RSDD in combination with a rodent cancer progression model, several known and novel genes displaying either elevated, progression-elevated gene (PSGen), or reduced expression, progression-suppressed gene (PSGen), were identified and cloned (6). Studies have currently focused on PSGen 13 which is expressed at higher levels in rodent cancer cells displaying a non-progressed transformed phenotype (6), i.e., low growth efficiency in agar and extended tumor latency times in animals (7-10). PSGen 13 was initially identified as a novel gene sequence without homology to previously expressed genes (6). A full-length rat PSGen 13, rat PSGen 13, gene was produced and evaluated for biological activity in rodent and human tumor cells. These studies demonstrate that stable expression of rat PSGen 13 in a progressed adenovirus type 5-transformed Sprague-Dawley rat embryo clone, E11-NMT, results in a suppression of the progression phenotype. Suppression is associated with a reduction in anchorage independent growth to a level that is apparent in unprogressed, E11, transformants. Moreover, progression suppressed transformed clones also display a reduction in transcription of the progression elevated gene, PEG-3 (11,12), and VEGF (12). In DU-145 human prostate cancer cells, rat PSGen 13 transfected clones have also been identified that display a reduction in anchorage independence. These findings suggest that rat PSGen 13 can functionally alter the state of progression of rodent and human tumor cells. In addition, on the basis of the rat PSGen 13 sequence a human PSGen 13, HuPSGen 13, gene with significant homology to the rodent gene has been isolated.

MATERIALS AND METHODS

Cell cultures and agar growth assays. E11 is a single cell clone

of H5ts125-transformed Sprague-Dawley secondary RE cells (13). E11-NMT is a subclone of E11 cells derived from a nude mouse tumor induced by the E11 cell line (10). R12 is a Ha-ras oncogene transformed E11 clone (14). F1 and F2 are suppressed somatic cell hybrids with a flat morphology that were formed between E11-NMT and CREF cells (15). R1 and R2 are progressed somatic cell hybrids with a round morphology that were created by fusing E11-NMT and CREF cells (15). E11-HPV E6/E7 is a clone of E11 cells transformed with E6/E7 gene region of human papilloma virus type 18 (11). E11 x E11-NMT A6 and 3b are independent somatic cell hybrid clones formed between E11 and E11-NMT cells that do not display the progression phenotype (16). E11 X E11-NMT A6TD is a progressed somatic cell hybrid formed by isolating a tumor induced in a nude mouse by the E11 X E11-NMT A6 somatic cell hybrid (11,16). E11 X E11-NMT IIa is a somatic cell hybrid formed between E11 and E11-NMT that exhibits the progression phenotype (16). E11-NMT Aza B1 and Aza C1 are independent clones of E11-NMT cells treated with 5-azacytidine and displaying suppression in the progression phenotype (11,16). CREF is a specific immortal non-transformed and non-tumorigenic clone of Fischer rat embryo fibroblast cells (17). DU-145 is a hormone refractive human prostate carcinoma cell line (18). All cultures were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% FBS (DMEM-5) at 37°C in a humidified 5% CO₂ 95% air incubator. Anchorage independent growth assays were performed as described previously by seeding variable number of cells in 0.4% noble agar containing medium on a base layer of 0.8% noble agar containing medium (6-13).

Construction of PSGen 13 expressing E11-NMT clones. E11-NMT and DU-145 cells were transfected with a pcDNA3.1 (+) expression vector (containing a neomycin resistance gene) lacking or having the complete PSGen 13 gene as previously described (11). Briefly, 1 X 10⁵ cells were seeded in 10-cm tissue culture plates, 6 hr later 10 μ g of purified pcDNA3.1 (+) vector or a rat PSGen 13/pcDNA3.1 (+) construct was incubated with 30 μ l of

Lipofectamine (Gibco BRL) and this mixture was added to cells for 8 hr. The next day the media was changed with the addition of 500 $\mu\text{g}/\text{ml}$ of G418 and media was changed 2X per week for three weeks. G418-resistant colonies were isolated using cloning cylinders and maintained as independent cell lines, referred to as NMT-PSG13 clones (cl 3, 5, 6, 7, 8, 9, 10, 11 and 12) and DU-PSG13 clones (cl 11, 12, 13, 14, 15 and 17), in complete media containing 100 $\mu\text{g}/\text{ml}$ of G418. Additionally, NMT-vector and DU-145-Vec clones were isolated and maintained as independent cell lines in complete media containing 100 $\mu\text{g}/\text{ml}$ of G418.

Northern blotting assays. Total cellular RNA was isolated by the guanidinium/phenol extraction method and Northern blotting was performed as described (11). Fifteen μg of RNA were denatured and electrophoresed in 1.2% agarose gels with 3% formaldehyde, transferred to nylon membranes and hybridized sequentially with a ^{32}P -labeled rat PSGen 13 cDNA probe, the blot was stripped and then reprobed with a ^{32}P -labeled GAPDH cDNA probe as described previously (11). Following hybridization, the filters were washed and exposed for autoradiography.

Promoter analyses. To evaluate the activity of the full length rat PEG-3 promoter (PEG-Prom) and VEGF-Promoter constructs, cells (E11, E11-NMT and NMT-PSGen13) clones, were seeded at 2×10^5 / 35-mm tissue culture plate and -24 h later transfected with 5 μg of the PEG-Prom-luciferase or VEGF-Prom-Luciferase constructs plus 1 μg of SV40- β -gal Vector (Promega) mixed with 10 μl of Lipofectamine Reagent (Gibco) in 200 μl of serum-free media. After 20 min at RT, 800 μl of serum-free media were added resulting in a final volume of 1 ml. The transfection mixture was removed after 14 hr and the cells were washed 3X with serum-free media and incubated at 37°C for an additional 48 hr in complete growth media. Cells were harvested and lysed to make extracts (19) utilized in β -gal and Luciferase reporter assays. Luminometric determinations of Luciferase and β -gal activity was

performed using commercial kits (Promega and Tropix, respectively). For Luciferase assays, 10 μ l of cell lysate were mixed with 40 μ l of Luciferase Assay substrate (Promega). For β -gal assays, 10 μ l of the cell lysate were mixed with 100 μ l of diluted Galecton-Plus with 150 μ l of Accelerator (Tropix). Promoter analysis data were collected a minimum of three times using triplicate samples for each experimental point and the data was standardized with the β -gal data.

Cloning a full length rat PSGen 13 and a HuPSGen 13 cDNA. An original rat PSGen 13 EST was identified using RSDD and reverse Northern hybridization as a gene displaying elevated expression in E11 versus E11-NMT cells (6). A full length open reading frame (ORF) of rat PSGen 13 was cloned using the complete open reading frame (C-ORF) approach with gene specific primers (20) and electronic data mining based on the EST sequence. Primers used for C-ORF were PSGen13-R2 (TCG CTT CTC ACT TTG ACG GAG TGT CAA G) (SEQ ID NO: __) and PSGen13-R2 Nested (TGT CAA GTG TGG CAG AGA CTA AGA ATG G) (SEQ ID NO: __). In addition, full length rat PSGen 13 and HuPSGen 13 cDNA clones were identified by sequence comparison of the rat PSGen 13 EST sequence with GenBank by BLAST. Selected clones (ATCC #2005777 from rat PSGen 13 and ATCC #2525262 for HuPSGen13) were procured (Research Genetics) and sequenced.

Experimental Results

Sequence Informatics of PSGen 13. The cloned full length rat PSGen 13 cDNA consists of 780 bp excluding the poly(A) tail. A poly(A) signal (AATAAA) is located at position 763 (Fig. 1) (SEQ ID NO: __). The ORF starts at the first ATG at 170 bp followed by in-frame stop codon at 86 bp and spans to 415 bp. Rat PSGen 13 encodes a protein with predicted 81 amino acids of calculated molecular weight of 9 kDa with a pI of 5.52 (Fig. 1). Protein sequence analysis did not indicate hydrophobic patches for

membrane spanning regions or signal peptide sequences characteristic of secretory proteins. Motif and pattern analysis also failed to identify sequence homologies with previously reported genes, information that is useful in providing potential insights into the biological function and or mode of action of rat PSGen 13. Based on this observation, rat PSGen 13 appears to encode a novel class of proteins.

A human homologue of Rat PSGen 13 (HuPSGen 13) was electronically cloned by analyzing sequences reported in the GenBank data base (Fig. 2) (SEQ ID NO:___). HuPSGen 13 is 75% identical to rat PSGen 13 at the nucleotide level, but 94% identical to Rat PSGen 13 on a protein level (79/81) (Figs. 3 and 4). Of the 5 residues that are distinct in HuPSGen 13, three of them (D at 4, K at 38 and I at 77) are conserved substitutions of rat PSGen 13 (E at 4, R at 38 and V at 77, respectively), which suggests strong conservation in functionality. Furthermore, sequence identity of HuPSGen 13 with rat PSGen 13 protein is 87% at the nucleotide level. Both 5' and 3' untranslated regions display 68.7% and 68.3% identity, respectively, and are more diverse between rat PSGen 13 and HuPSGen 13 than the ORF, which is not uncommon between interspecies homologues. Considering the degree of conservation in the ORF and resulting protein sequence, HuPSGen is an orthologue of rat PSGen 13. The cloned HuPSGen 13 cDNA consists of 835 bp excluding the poly(A) tail and a canonical poly(A) signal was observed at 814 bp. Although an in-frame stop codon was not present, the ORF of HuPSGen 13 starts at the first ATG (197 bp) and runs through 442 bp. HuPSGen 13 encodes 81 amino acids of calculated Mol. Wt. of 9 kDa with a pI of 5.86. As in rat PSGen 13, computational protein sequence analysis did not yield any known functional motifs.

Rat PSGen 13 Suppresses Anchorage Independent Growth in E11-NMT and DU-145 Cells. Rat PSGen 13 was identified using RSDD as a gene displaying elevated expression in E11 cells versus E11-NMT cells (6). Using a panel of rodent cell lines displaying either

a progressed phenotype (+), as indicated by elevated growth in agar and short tumor latency times, or unprogressed (-), as indicated by reduced growth in agar and extended tumor latency times, a direct correlation between reduced rat PSGen 13 expression and the progression phenotype was found (Fig. 5) (6). The level of rat PSGen 13 was elevated in E11, CREF X E11-NMT F1 and F2, E11 X E11-NMT A6, and E11-NMT AZA B1 cells which do not display the progression phenotype. In contrast, rat PSGen 13 expression was lower in progressed E11-NMT, CREF X E11-NMT R1 and R2, E11 X E11-NMT A6TD, E11 X E11-NMT IIa, E11-Ras R12 and E11-HPV E6/E7 cells. These findings documented a potential inverse relationship between expression of the progression phenotype and rat PSGen 13 expression. They also raised the possibility that PSGen 13 might play a functional role in the progression process.

A full-length rat PSGen 13 was isolated using the C-ORF procedure (20), cloned into an expression vector and stably transfected into E11-NMT and DU-145 cells. Random clones were isolated and evaluated for their ability to form macroscopic colonies when seeded in semi-solid agar (7-9). E11 cells grow with a low efficiency in agar, whereas progressed E11-NMT cells display elevated growth in agar, forming more and larger colonies than E11 cells (Fig. 6) (7-10). Analysis of the random NMT-PSGen 13 clones, designated as NMT-PSG13 cl number, indicated specific clones displaying no significant reduction in anchorage independence, i.e., NMT-PSG13 cl 3 and 5, and clones displaying reduced agar cloning efficiencies similar to E11 cells, i.e., NMT-PSG13 cl 7 and 12. In addition, a number of clones were also identified that display a significant reduction in anchorage independence versus E11-NMT cells, but less growth suppression than NMT-PSG13 cl 7 and 12, including NMT-PSG13 cl 6, 8, 9, 10, and 11. To confirm that suppression of anchorage independence was associated with increased expression of PSGen 13, total RNA was isolated from E11, E11-NMT and NMT-PSG13 cl 3, 5, 7 and 12 and evaluated by Northern blotting (Fig. 7). This experiment

documented expression of PSGen 13 in E11 and NMT-PSG13 cl 7 and 12, but not in E11-NMT or NMT-PSG13 cl 3 and 5. These results demonstrate that forced expression of PSGen-13 in E11-NMT cells results in a suppression of anchorage independent growth, a marker of the progression phenotype in this transformation model system.

To determine if the rat PSGen 13 gene could effect the transformed phenotype in human cancer cells, a full-length Rat PSGen 13 cDNA was transfected into DU-145 human prostate cancer cells and random clones were isolated. The clones were then evaluated for anchorage independent growth (Fig. 8). Several clones were identified, including DU-PEG13 cl 11, 12 and 14, that displayed a significant reduction in anchorage independent growth in comparison with DU-145 cells. Additional clones, including a vector transfected clone and DU-PEG13 cl 13, 15 and 17 displayed similar cloning efficiencies in agar as untransfected DU-145 cells. These results demonstrate that rat PSGen 13 can also suppress the transformed phenotype in human cancer cells, thereby indicating a more general inhibitory capacity of this gene product in tumor cells.

Rat PSGen 13 Inhibits Transcriptional Activity in E11-NMT Cells.

Previous studies indicate that E11-NMT cells display elevated transcription of the PEG-3 and VEGF genes as compared to E11 cells (12). These changes in gene expression are believed to be important determinants of the aggressive progressed cancer phenotype of E11-NMT versus E11 cells (12). To determine if rat PSGen 13 expression can effect these important progression related genes, the transcriptional activities of PEG-Prom-Luciferase and VEGF-Prom-Luciferase constructs were evaluated in E11, E11-NMT and the different NMT-PSG13 clones (Figs. 9 and 10). As previously reported (12), the PEG-Prom and VEGF-Prom were more active in E11-NMT than in E11 cells. Both NMT-PSG13 cl 7 and 12 displayed a reduction in PEG-Prom activity similar to that of E11 cells (Fig. 9). In contrast, when

compared with E11-NMT cells the levels of PEG-Prom-Luciferase activity were unchanged in NMT-PSG13 cl 3 and 5, which do not express elevated Rat PSGen 13 mRNA (Fig. 7). Although of lesser magnitude than observed in NMT-PSG13 cl 7 and 12, reductions in the level of PEG-Prom activity were also apparent in NMT-PSG13 cl 6 (smallest reduction), 8, 9, 10 and 11. In the case of the VEGF-Prom, no change in promoter activity was apparent in NMT-PSG13 cl 3 and 5 versus E11-NMT cells (Fig. 10). However, a similar reduction in VEGF-Prom activity, approaching that observed in E11 cells, was apparent in NMT-PSG13 cl 7, 8, 9, 10, 11 and 12. These results suggest that expression of PSGen 13 can regulate expression of both PEG-3 and VEGF. It is not presently known if this regulation of the transcriptional activity of either of these two genes occurs by a direct or indirect mechanism.

Conclusions

The RSDD approach has successfully identified a novel gene, Rat PSGen 13, that can functionally regulate cancer progression in both rodent and human tumor cells. Evidence is presented that forced expression of Rat PSGen 13 in rodent tumor cells displaying an aggressive cancer phenotype, E11-NMT, results in a suppression of the cancer phenotype as monitored by a reduction in anchorage independent growth. Similarly, when overexpressed in a human prostate cancer cell line (DU-145), rat PSGen 13 also induces an inhibition in anchorage independence. The mechanism by which PSGen 13 induces its cancer growth suppression properties is not known. However, in the E11-NMT model forced expression of rat PSGen 13 directly correlates with a suppression in the transcriptional activities of two significant cancer progression regulating genes, PEG-3 and VEGF. Based on sequence homology, a human PSGen 13 gene, HuPSGen 13, has been isolated. Since this gene is highly homologous to the rat PSGen 13 gene, 75% and 94% on a nucleotide and protein level, respectively, there is a high probability that the HuPSGen 13 gene will behave

biologically in a similar manner as the rat gene, i.e., it will function as a suppressor of the cancer phenotype and tumor progression. Although further studies are required, the present studies provide initial support for the potential use of PSCN 13 for the targeted therapy of human cancer.

5

279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295
2296
2297
2298
2299
2300
2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
2373
2374
2375
2376
2377
2378
2379
2380
2381
2382
2383
2384
2385
2386
2387
2388
2389
2390
2391
2392
2393
2394
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
2428
2429
2

References

1. Fisher, P.B. (1984). In: Tumor Promotion and Cocarcinogenesis In Vitro, Mechanisms of Tumor Promotion.
- 5 Slaga T. J. (ed). CRC Press, Inc., Boca Raton, FL, pp. 57-123.
2. Bishop, J.M. (1991). Cell, 64, 235-248.
3. Knudson, A.G. (1993). Proc. Natl. Acad. Sci. USA, 90, 10914-10921.
4. Levine, A.J. (1993). Annu. Rev. Biochem., 62, 623-651.
- 10 5. Vogelstein, B. & Kinzler, K.W. (1993). Trends Genet., 9, 138-141.
6. Kang, D.-C., LaFrance, R., Su, Z.-z. & Fisher, P. B. (1998) Proc. Natl. Acad. Sci. USA, 95, 13788-13793.
7. Fisher, P.B., Goldstein, N.I. & Weinstein, I.B. (1979a). Cancer Res., 39, 3051-3057.
- 15 8. Fisher, P.B., Dorsch-Hasler, K., Weinstein, I.B. & Ginsberg, H.S. (1979b). Nature, 281, 591-594.
9. Fisher, P.B., Bozzone, J.H. & Weinstein, I.B. (1979c). Cell, 18, 695-705.
- 20 10. Babiss, L. E., Zimmer, S.G. & Fisher, P.B. (1985). Science, 228, 1099-1101.
11. Su, Z.-z., Shi, Y. & Fisher, P.B. (1997) Proc. Natl. Acad. Sci. USA, 94, 9125-9130.
12. Su, Z.-z., Goldstein, N.I., Jiang, H., Wang, M.-N., Duigou, G.J., Young, C.S.H. & Fisher, P.B. (1999) Proc. Natl. Acad. Sci. USA, 96, 15115-15120.
- 25 13. Fisher, P.B., Weinstein, I.B., Eisenberg, D. & Ginsberg, H.S. (1978). Proc. Natl. Acad. Sci. USA, 75, 2311-2314.
14. Duigou, G.J., Babiss, L.E. & Fisher, P.B. (1989). NY Acad. Sci., 567, 302-306.
- 30 15. Duigou, G.J., Babiss, L.E., Iman, D.S., Shay, J.W. & Fisher, P.B. (1990). Mol. Cell. Biol., 10, 2027-2034.
16. Reddy, P.G., Su, Z.-z. & Fisher, P.B. (1993). In: Chromosome and Genetic Analysis, Methods in Molecular Genetics. Adolph K. W. (ed). Vol 1. Academic Press, Inc., Orlando, FL, pp. 68-102.
- 35

17. Fisher, P.B., Babiss, L.E., Weinstein, I.B. & Ginsburg, H.S. (1982). Proc. Natl. Acad. Sci. USA, 79, 3527-3531.
18. Jiang, H., Su, Z.-z., Lin, J.J., Goldstein, N. I., Young, C. S. H. & Fisher, P. B. (1996) Proc. Natl. Acad. Sci. USA, 93, 9160-9165.
19. Gopalkrishnan, R.V., Christiansen, K., Goldstein, N.I., DePinho, R.A. & Fisher, P.B. (1999). Nucl. Acids Res., .27, 4775-4782.
20. Kang, D.-C. & Fisher, P.B. (2000). Unpublished data.

What is claimed is:

1. An isolated nucleic acid encoding a Progression Suppressed Gene 13 (PSGen 13) protein.
2. The isolated nucleic acid of claim 1, wherein the Progression Suppressed Gene 13 (PSGen 13) protein is a human protein, a rat protein, a primate protein, a mouse protein, or a bovine protein.
3. The isolated nucleic acid of claim 1, wherein the nucleic acid comprises the polynucleotide sequence shown in SEQ ID NO:1.
4. The isolated nucleic acid of claim 1, wherein the nucleic acid comprises the polynucleotide sequence shown in SEQ ID NO:2.
5. The isolated nucleic acid of claim 1, wherein the nucleic acid consists essentially of the polynucleotide sequence shown in SEQ ID NO:1.
6. The isolated nucleic acid of claim 1, wherein the nucleic acid consists essentially of the polynucleotide sequence shown in SEQ ID NO:2.
7. The isolated nucleic acid of claim 1, wherein the nucleic acid consists of the polynucleotide sequence shown in SEQ ID NO:1.
8. The isolated nucleic acid of claim 1, wherein the nucleic acid consists of the polynucleotide sequence shown in SEQ ID NO:2.
9. A vector comprising the nucleic acid of any one of claims

1 to 8.

10. A host cell comprising the vector of claim 9.

5 11. The host cell of claim 10, wherein the host cell is a tumor cell.

12. The host cell of claim 11, wherein the tumor cell is a nasopharyngeal tumor cell, a thyroid tumor cell, a central nervous system tumor cell, a melanoma cell, an epithelial tumor cell, a non-epithelial tumor cell, a blood tumor cell, a leukemia cell, a lymphoma cell, a neuroblastoma cell, a cervical cancer cell, a breast cancer cell, a lung cancer cell, a prostate cancer cell, a colon cancer cell or a glioblastoma multiforme cell.

13. A method for treating cancer in a subject which comprises contacting a cell of the subject with a nucleic acid encoding a Progression Suppressed Gene 13 Protein (PSGen 13) in a sufficient amount so as to cause the cell to express the PSGen 13 protein, thereby treating cancer in the subject.

14. The method of claim 13, wherein the cell is a tumor cell.

15. The method of claim 14, wherein the tumor cell is a nasopharyngeal tumor cell, a thyroid tumor cell, a central nervous system tumor cell, a melanoma cell, an epithelial tumor cell, a non-epithelial tumor cell, a blood tumor cell, a leukemia cell, a lymphoma cell, melanoma cell, a neuroblastoma cell, a cervical cancer cell, a breast cancer cell, a lung cancer cell, a prostate cancer cell, a colon cancer cell or a glioblastoma multiforme cell.

16. The method of claim 13, wherein the subject is suffering from a form of cancer.

17. The method of claim 16, wherein the form of cancer is melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, chondrosarcoma, a nasopharyngeal tumor, a thyroid tumor, a central nervous system tumor, a melanoma, an epithelial tumor, a non-epithelial tumor, a blood tumor, a leukemia, a lymphoma.

18. The method of claim 13, wherein the contacting is by way of topical application, administration to the subject, injection, electroporation, liposome application, viral-mediated contact, contacting the cell with the nucleic acid, or coculturing the cell with the nucleic acid.

19. The method of claim 18, wherein the contacting is carried out via injection, oral administration, topical administration, adenovirus infection, viral-mediated infection, liposome-mediated transfer, topical application to the cells of the subject, or microinjection.

20. The method of claim 13, wherein the subject is a mammal.

21. The method of claim 20, wherein the mammal is a human.

22. An isolated Progression Suppressed Gene 13 (PSGen 13) protein.

23. The protein of claim 22, wherein the protein is a human protein, a rat protein, a bovine protein, a mouse protein, or a primate protein.

24. The protein of claim 22, wherein the protein has a polypeptide sequence which is encoded by the polynucleotide sequence of SEQ ID NO:1.

25. The protein of claim 22, wherein the protein has a polypeptide sequence which is encoded by the polynucleotide sequence of SEQ ID NO:2.

26. An antibody which binds specifically to the protein of any one of claims 22 to 25.

27. The antibody of claim 26, wherein the antibody is a polyclonal antibody or a monoclonal antibody.

28. The antibody of claim 26, wherein the antibody is a human antibody, a murine antibody, a primate antibody, a bovine antibody, a sheep antibody or a rat antibody.

29. The antibody of claim 26, wherein the antibody is a human monoclonal antibody, a humanized murine monoclonal antibody, a humanized primate monoclonal antibody, or a humanized rat monoclonal antibody.

30. A composition which comprises any one of the nucleic acids of claims 1 to 8 and a carrier.

31. The composition of claim 30, wherein the composition is a pharmaceutical composition.

32. A composition which comprises any one of the proteins of claims 22 to 25 and a carrier.

33. The composition of claim 32, wherein the composition is a pharmaceutical composition.

34. A composition which comprises the antibody of claim 26 and a carrier.

35. The composition of claim 34, wherein the composition is a pharmaceutical composition.

36. A method for inhibiting growth of a cancer cell which comprises contacting the cancer cell with a pharmaceutical composition comprising a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator compound in a sufficient amount so as to inhibit growth of the cancer cell.

37. The method of claim 36, wherein the PSGen 13 activator compound comprises a transcription factor which specifically activates expression of a PSGen 13 gene, an agent which prolongs PSGen 13 protein half-life in the cell, or a compound which stabilizes PSGen 13 mRNA in the cell so as to increase translation of PSGen 13 protein in the cell.

38. The method of claim 36, wherein the contacting is by way of topical application, injection, electroporation, liposome application, or coculturing the cell with the nucleic acid.

39. The method of claim 36, wherein the cancer cell is a nasopharyngeal tumor cell, a thyroid tumor cell, a central nervous system tumor cell, a melanoma cell, an epithelial tumor cell, a non-epithelial tumor cell, a blood tumor cell, a leukemia cell, a lymphoma cell, a melanoma cell, a neuroblastoma cell, a cervical cancer cell, a breast cancer cell, a lung cancer cell, a prostate cancer cell, a colon cancer cell or a glioblastoma multiforme cell.

40. A method for inhibiting angiogenesis associated with tumor growth in a subject which comprises administering to the subject a pharmaceutical composition comprising a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator compound in a sufficient amount so as to inhibit angiogenesis associated with tumor growth in the subject.

41. The method of claim 40, wherein the subject is a mammal.

42. The method of claim 41, wherein the mammal is a human.

43. The method of claim 40, wherein the subject is suffering from melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, chondrosarcoma, a nasopharyngeal tumor, a thyroid tumor, a central nervous system tumor, a melanoma, an epithelial tumor, a non-epithelial tumor, a blood tumor, a leukemia, or a lymphoma.

Progression Suppressed Gene 13 (PSGen 13) And Uses Thereof

Abstract of the Disclosure

The invention provides for an isolated nucleic acid encoding a Progression Suppressed Gene 13 (PSGen 13) protein. The invention also provides a vector comprising said nucleic acid and a host cell comprising said vector. The invention provides for an isolated Progression Suppressed Gene 13 (PSGen 13) protein. The invention also provides a method for treating cancer in a subject which comprises contacting a cell of the subject with a nucleic acid encoding a Progression Suppressed Gene 13 Protein (PSGen 13) in a sufficient amount so as to cause the cell to express the PSGen 13 protein, thereby treating cancer in the subject. The invention also provides a method for inhibiting growth of a cancer cell which comprises contacting the cancer cell with a pharmaceutical composition comprising a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator compound in a sufficient amount so as to inhibit growth of the cancer cell.

Figure 1

```

GGCAGGAGCTCTCCTCGTCCCTCCCTTCTCCACTGCAGCCTTTCTCTTAGCCCCAACCA 60
CTTCCTTCTTCTGCTTGTTCCTCCCTAGGGCGCGGAAGCTGAGTGCAGGGTTTACAGCCCA 120
CGCGGCGAGCAGCTCTTCAGTGAAGAAGGAAGCAATCGGAGGGTCAGCAATGAACGTGGA 180
                                     M N V E
GCATGAGGTTAACCTCCTGGTGGAGGAAATTCATCGTCTGGGTCCAAAAATGCCGATGG 240
H E V N L L V E E I H R L G S K N A D G
GAAACTGAGTGTGAAGTTTGGGGTCCCTTCCAAGACGACAGATGTGCCAATCTCTTTGA 300
K L S V K F G V L F Q D D R C A N L F E
AGCGTTGGTGGGAACCTGAAAGCCGCAAAACGAAGGAAGATTGTTACGTACGCAGGAGA 360
A L V G T L K A A K R R K I V T Y A G E
GCTGCTTTTGCAAGGTGTTTCATGATGATGTTGACATTGATTGCTGCAAGATTAATGTGG 420
L L L Q G V H D D V D I V L L Q D
TTTGCAATCTGGGGGTATCTGGTAAACTGGAATAATTAAGTTAAAGGACAAACATGAAG 480
TTCCTTATGTAATTTTATAGACCTTTGTAAACAAAAGGGGACTTGTTCAGAACTCCTGTT 540
TTTATACCTTGGAGCAAAACATTACAATGTAAAAATAAACAAAACCTGTTATTTTTTTTT 600
TCTTAAGAAGGTAATCGGGAGACGTAGGCAATAAAATGTTTTCAGAGGTGCGAAAAAGCT 660
TTTGTTTTCTTAAACCATCTCTAGTCTCTGCCACACTTGACACTCCGTCAAAAGTGAGAA 720
CGAACTAAAGACCAACTGCGGTGGAAAAATATTATGTTTATGTAATAAAAAAAATCATGT 780

```


Figure 2

GGCACGAGGCTTGAGCGCAGAAACACTTACTTTTCCCCCTACCGTGCTCCTCCTCCTCCA 60
 CAGCCGTCTTCTCTTTGCTCAGCCACTTCTTCTTCCGCTCACCTCCCCAGTGCAC 120
 TGAAGAAGGTAACCGGGTCCAGACCCACGCGCGCCAGTTCTCCGGCGGGAAGGAAAC 180
 GCGCAGAGAGGCGAGCAATGAATGTGGATCACGAGGTTAACCTCTTAGTGGAGGAAATTCA 240
 M N V D H E V N L L V E E I H
 TCCTTTGGGTTCAAAAAATGCTGATGGAAGTTAAGCGTGAATTTGGGGTCTCTTCCG 300
 R L G S K N A D G K L S V K F G V L F R
 TGATGATAAATGTCCCACTCTTTGAAGCATTGGTAGGAACCTTTAAAGCTGCAAAACG 360
 D D K C A N L F E A L V G T L K A A K R
 AAGGAAGATTGTAACATATCCAGGAGAGCTGCTTCTGCAAGGTGTTTCATGATGATGTTGA 420
 R K I V T Y P G E L L L Q G V H D D V D
 CATTATATTACTGCAAGATTAATGTGGTTTACATATCTTTATGTACTGCCATTTTTTGT 480
 I I L L Q D
 TCTGGTAAACTGGAATATAAAGTGARAGAACAACCACTTTGAACATACTTAATGTATTTTT 540
 ATAGAACTTTGTAAACGAAAGGAGATTCATGTTTTAGAACTGTGTCCTTTTATATCTT 600
 GAAAGAAAATCTATGATGATGCTATAAAATAAATCCTATTATTTTTCTCAGGAATCTGG 660
 TTAGGAATTCAGGCAATGAGATTTTTTGCAGGGCAGGGATGGGAAATGTTTGTTCATAAA 720
 TAATTAGACATTTTTCTATAGATATTTGACATTCTCGGAAAGCAACAAGCAAACTGAAGAC 780
 CAACTCCTATGAGAAATATTATGATGTTTATGTAATAAAGACATGTAACGTCTT 835

Figure 3

RatPSGen-13	-----GGACAGAGCTCTCTCTGTC-----CCCTCCCTCTCTCA	33
HuPSGen-13	GGCACAGGCTTGAGCGCAGAAACCTTACTTCCCTTCTCTCTCTCA	60
	*** ** *	
RatPSGen-13	CTGCAGCCTTTCTCTTAGCGGAACCACTTCTCTTCTGCTTGTTCCTCCCTAGGGCGC	93
HuPSGen-13	CAGCGGCTTTCTTCTTTGGCTCAGCACTTCTTCTTCTGCTCAOCCCTCCCGAGTGAC	120
	* *	
RatPSGen-13	GGAGACTGAGTGCAGGGTTCAGACCCACCGCGGAGCAGCTTCTCAGTGAAGAAGGAAGC	153
HuPSGen-13	TGAAGAAGGTACCCGGGTCAGACCCACCGCGGC-CAGTTCTCCGGCGGAAGGAAGAAC	179
	*** *	
RatPSGen-13	AAT-CGGAGGGGCAGCAATGAACGTGGAGCATAGAGTTAACTCCTGGTGGAGGAATTC	212
HuPSGen-13	CGCGCAGAGGTCAGCAATGATGTGATACAGAGGTTAACTCTTGTGGAGGAATTC	239
	* *	
RatPSGen-13	ATCGTTCTGGGTTCAAAAATGCCGATGGGAACCTAGTGTGAAGTTTGGGGTCTCTTCC	272
HuPSGen-13	ATCGTTTGGGTTCAAAAATGCTGATGGAAGTTAAGCTGAAATTTGGGGTCTCTTCC	299

RatPSGen-13	AAGACGACAGATGTGCCAATCTCTTTGAAGCGTGTGGTGGAACTCGAAGACCGCAAAAC	332
HuPSGen-13	GTGATGATAAATGTGCCAACCTCTTTGAAGCATTGATGAGACTCTAAGACTCGCAAAAC	359
	* *	
RatPSGen-13	GAAAGGAATGTGTACGTACGACGAGAGCTGCTTTTGAAGGTGTTCATGATGATGTG	392
HuPSGen-13	GAAAGGAATGTGTACATCTCAGGAGAGCTGCTCTGCAAGGTGTTCATGATGATGTG	419

RatPSGen-13	ACATTGTATGCTGCAAGATTAAATGTGGTTTGCAGATCTGGGGTA-----	438
HuPSGen-13	ACATTATATTACTGCAAGATTAAATGTGGTTTGCAGATCTTATGACTGCCATTTTTGT	479

RatPSGen-13	-TCTGGTAACTGGAATAATTAAGTTAAAGGCAAAACAT---GAAGTCTCTATGTATTT	494
HuPSGen-13	TCTCTGTAACTGGAAAT-TAAAGTGAAGGCAAAACATTGAACATCTATGTATTT	538

RatPSGen-13	TTATAGACCTTTGTAACAAAGGGGATCTGT---TGAGAACTG---CTGTTTATATACC	548
HuPSGen-13	TTATAGACCTTTGTAACGAAGAGAGATCATGTTTGAAGAGTCTGCTCTTTATATATC	598

RatPSGen-13	TTGGAGCAAAACATTACAATGTAAATAAACAACAACTGTTATTTTTTTTCTTAAGA	608
HuPSGen-13	TTGAAGAAATCT---ATGATGATGCTATAAAATAAATCCTATATTTTTCTCAGGA	654
	* *	
RatPSGen-13	AGGTAATCGGGAGCAGTAGGCAATAAAATGTTTTCAGAGTGCAGAAAGCCTTTGTTTT	668
HuPSGen-13	ATCTGTTAGGAATGCAGGCAATAGATTTTTTGGGGGCGAGGATGGGAATGTTTGT	714
	* - *	
RatPSGen-13	CTTAAGACCATTC-TAGTCTCTGTC-ACACTTGCAGTCTCGCAAGTGAGAGCGAAGCT	726
HuPSGen-13	CATAAATAATTAGACATTTTCTATAGATATTGACATCTCCGAGCAACAGCAACT	774
	* *	
RatPSGen-13	AAAGCAACCATCGGGTGGAAATATATG---TTTATGTAATAAAAAAATCA-TGT--	780
HuPSGen-13	GAAGCAACCATCTCATAGAAATATATGATGTGTATGTAATAAAGCACTAGACTGTCT	834

RatPSGen-13	-	
HuPSGen-13	T 835	

Figure 4

RatpSGen-13
HuPpSGen-13

MMNVEHEVNLLVEE IHRLGSKNADGKLSVKFGLVFQDDRCANLFEALVGTTLKAARKRKIVT 60
MMNVEHEVNLLVEE IHRLGSKNADGKLSVKFGLVFQDDRCANLFEALVGTTLKAARKRKIVT 60
:**:*****:*****:*****:*****:*****:*****:*****:*****:*****

RatpSGen-13
HuPpSGen-13

YAGELLQGVHDDVDVILLQD 81
YFCELLQGVHDDVDVILLQD 81
* *****:*****:*****

Figure 5




Figure 6

PSGen 13 Suppresses the Transformed Phenotype in E11-NMT Cells




Figure 7





Figure 8

Rat PSGen 13 Inhibits Anchorage Independent Growth in DU-145 Cells



SCAN 11
Q.

Figure 9

PSGen 13 Suppresses PEG-3 Promoter Activity in E11-NMT Cells




Figure 10

PSGen 13 Suppresses VEGF Promoter Activity in E11-NMT Cells




Figure 7




Figure 8
Rat PSGen 13 Inhibits Anchorage
Independent Growth in DU-145 Cells




Figure 9
PSGen 13 Suppresses PEG-3 Promoter
Activity in E11-NMT Cells





Figure 10
PSGen 13 Suppresses VEGF Promoter
Activity in E11-NMT Cells



Applicants: Paul B. Fisher, et al.

U.S. Serial No.:

Filed: August 25, 2000

Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
<u>N/A</u>		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
<u>N/A</u>		

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923) and Raymond A. Diperna (Reg. No. 44,063).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Applicants: Paul B. Fisher, et al.

U.S. Serial No.:

Filed: August 25, 2000

Declaration and Power of Attorney

Page 3

Please address all communications, and direct all telephone calls, regarding this application to:

John P. White

Reg. No. 28,678

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or

first joint inventor

Paul B. Fisher

Inventor's signature

Citizenship United States

Date of signature

Residence 15 Gordon Place, Scarsdale, New York, 10583, U.S.A.

Post Office Address

same as above

Full name of joint

inventor (if any)

Dong-Chul Kang

Inventor's signature

Citizenship Korea

Date of signature

Residence 200 Union Avenue, Apartment A, Rutherford, New Jersey, 07070, USA

Post Office Address

same as above

Full name of joint

inventor (if any)

Zao-Zhong Su

Inventor's signature

Citizenship People's Republic of China Date of signature

Residence 705 West 170th Street, Apartment 24, New York, New York 10032

Post Office Address

same as above